Half-Life Extension Enhances Drug Efficacy in Adeno-Associated Virus Delivered Gene Therapy

Wu, Huifang; Hu, Dan; Li, Quanxiao; Wang, Qianqian; Zhu, Xiao‐Dong; Li, Wei; Chen, Binfan; Ji, Ping; Huang, Keke; Huang, Ailing; Huang, Jinghe; Dimitrov, Dimiter S.; Wu, Yanling; Ying, Tianlei

doi:10.1016/j.eng.2022.02.009

Cited by 1 publication

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the single-chain Fc-fused n425 maintains a favorable in vivo pharmacokinetic pro le based on preserved FcRn binding despite its smaller size [25][26][27][28][29] . Alternatively, the fusion of n425 with albuminbinding UdAbs also offers a potential strategy to prolong the half-life of UdAbs 30 .…”

Section: Discussionmentioning

confidence: 99%

Fully human single-domain antibody targeting a highly conserved cryptic epitope on the Nipah virus G protein

Ying,

Wang,

Sun

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Nipah virus infection, one of the top priority diseases recognized by the World Health Organization, underscores the urgent need to develop effective countermeasures against potential epidemics and pandemics. Here, we identified a fully human single-domain antibody that targets a highly conserved cryptic epitope situated at the dimeric interface of the Nipah virus G protein (receptor binding protein, RBP), as elucidated through structures by high-resolution cryo-electron microscopy (cryo-EM). This unique binding mode disrupts the tetramerization of the G protein stalk domain, consequently obstructing the activation of the F protein and inhibiting viral membrane fusion. Furthermore, our investigations revealed that this compact antibody displays enhanced permeability across the blood-brain barrier (BBB) and demonstrates superior efficacy in eliminating pseudovirus within the brain in a murine model of Nipah virus infection, particularly compared to the well-characterized antibody m102.4 in an IgG1 format. Consequently, this single-domain antibody holds promise as a therapeutic candidate to prevent Nipah virus infections and has potential implications for vaccine development.

show abstract